Christopher Turner

Christopher Turner

Technik-/Wissenschafts-/F&E-Leiter bei NUVALENT, INC.
58 Jahre
Health Technology
Health Services
Consumer Services

Profil

Dr. Christopher D.
Turner
, MD, is a Chief Medical Officer at Nuvalent, Inc. Dr. Turner was previously employed as a Vice President-Clinical Development by Blueprint Medicines Corp., a Vice President-Clinical Science by Celldex Therapeutics, Inc., a Head-Clinical Research by ARIAD Pharmaceuticals, Inc., a Director-Pediatric Neuro Oncology Outcomes by Dana-Farber Cancer Institute, Inc., and a Director-Pediatric Neuro Oncology Outcomes Clinic by The Children's Hospital Corp.
He received his undergraduate degree from Bowdoin College and a doctorate degree from the University of Rochester School of Medicine & Dentistry.

Aktive Positionen von Christopher Turner

UnternehmenPositionBeginn
NUVALENT, INC. Technik-/Wissenschafts-/F&E-Leiter 01.03.2021

Ehemalige bekannte Positionen von Christopher Turner

UnternehmenPositionEnde
BLUEPRINT MEDICINES CORPORATION Corporate Officer/Principal 01.03.2021
CELLDEX THERAPEUTICS, INC. Corporate Officer/Principal 01.05.2018
ARIAD PHARMACEUTICALS, INC. Technik-/Wissenschafts-/F&E-Leiter 01.07.2014
Corporate Officer/Principal -
Corporate Officer/Principal -
Sehen Sie sich die Erfahrung von Christopher Turner im Detail an

Ausbildung von Christopher Turner

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

45

Beziehungen ersten Grades

8

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen8

Health Technology

Health Services

Consumer Services

Health Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Börse
  2. Insiders
  3. Christopher Turner